Skip to content
Whale Atlas — Follow the signal.
Home
FULL RECORDS
All Congress filingsSearch insider filings
MORE TOOLS
WatchlistGold IntelligenceSilver IntelligencePeopleCharts & technicalsCompany financialsOfficial newsMy saved workspace
YOUR RESEARCH
HomeAll Congress filingsSearch insider filings
More research tools
ExploreGold IntelligenceSilver IntelligencePeopleInvestigate an ideaCharts & technicalsMore evidenceCompany financialsOfficial newsMy research & helpWatchlistMy saved workspaceLearn the basicsHow signals workData & coverage
RESOURCES
LearnMethodologyData sources
Built on public evidence.

Primary sources. Clear reasoning.
No black boxes.

Our approach
Public research workspacev1.0

Loading data…

HomeSearchCongressWatchlist
© 2026 Whale AtlasFree public-filing research. Not financial advice. By using this site you agree to the Terms of Use.
FAQCompare trackersMethodologyData & correctionsTermsPrivacy
LOOK INSIDE THE BUSINESS

Company financials.

Explore company-wide revenue, income and balance-sheet facts directly from SEC filings.

View PMCB insider activity ↗

PMCBPharmaCyte Biotech, Inc.

THE LATEST REPORTED YEAR

The company reported a loss.

$19.42M net loss for the year ended April 30, 2026. These are reported results, not a forecast or a stock recommendation.

Revenue$0Year ended April 30, 2026
Profit or loss-$19.42MYear ended April 30, 2026
Cash from the business-$5.15MYear ended April 30, 2026
Total assets$36.71MAs of July 31, 2026
Total liabilities$6.9MAs of July 31, 2026
Cash & equivalents$17.74MAs of July 31, 2026
THE BUSINESS BEHIND THE TICKER

Revenue, over time.

Latest-filed standard financial facts · USD

$0
2019-04
$0
2020-04
$0
2021-04
$0
2022-04
$0
2023-04
$0
2024-04
$0
2025-04
$0
2026-04

Bars show magnitude; labels retain the sign. Each observation covers a reported annual period of 330–400 days; transition years can differ.

From the filing

Reported periods can differ from calendar years. Later filings may restate earlier figures. These are company-wide facts; product and geographic revenue segments are not included.

Reported periodReported valueFiledSource
May 1, 2025 – April 30, 2026$0July 29, 202610-K ↗
May 1, 2024 – April 30, 2025$0July 29, 202610-K ↗
May 1, 2023 – April 30, 2024$0August 11, 202510-K ↗
May 1, 2022 – April 30, 2023$0August 13, 202410-K ↗
May 1, 2021 – April 30, 2022$0July 31, 202310-K ↗
May 1, 2020 – April 30, 2021$0July 28, 202210-K ↗
May 1, 2019 – April 30, 2020$0August 10, 202110-K ↗
May 1, 2018 – April 30, 2019$0August 13, 202010-K ↗
Source and calculation details

One standard US-GAAP or IFRS concept is selected per metric, using USD only. Annual durations must be 330–400 days. Quarterly durations must be 70–110 days; year-to-date totals are excluded, and fourth quarters are never inferred by subtraction. Cash-flow quarters can therefore be sparse. Conflicting values filed on the same day are excluded. Latest-filed values are used, so these observations must not be treated as facts known in an earlier backtest.

Concept: us-gaap:Revenues · Retrieved October 12, 2026

Response SHA-256: 8f9ad1662a11f3cb167c6975b558c6cce5e582ddebd7699a946a7cffe2a40413

SEC company facts

Company-wide USD figures from SEC filings. Each card keeps its own reporting date; later filings can revise earlier results.